GSTM1 and hemolysis: Complement activity was assessed in serial samples from July 2024 to August 2025, during which the patient had multiple intravascular hemolysis episodes (Table 1; Figure 1), evidenced by Hb drops, reticulocytosis, and elevated LDH.